title: Human recombinant interferonalpha-2b for management of idiopathic recurrent superficial pyoderma in dogs: a pilot study.
abstract: The oral use of human recombinant interferonalpha-2b at 1,000 IU/ml/day appeared to provide only a transient benefit as compared with placebo for management of idiopathic recurrent superficial pyoderma in dogs. Further investigation using a larger population of dogs is needed to determine whether interferon is effective for long-term treatment of this condition.
authors.affiliation: Animal Allergy and Skin Disease Center, 6327 North Keystone Avenue, Indianapolis, IN, 46220, USA.
authors.forename: Lori A
authors.initials: LA
authors.lastname: Thompson
authors.forename: Terry L
authors.initials: TL
authors.lastname: Grieshaber
authors.forename: Larry
authors.initials: L
authors.lastname: Glickman
authors.forename: Nita
authors.initials: N
authors.lastname: Glickman
mesh_terms: D000284:Administration, Oral; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D011711:Pyoderma / Q000188:drug therapy / Q000662:veterinary*; D011994:Recombinant Proteins; D012008:Recurrence; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000662:veterinary*; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins